Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma

Oncology (Switzerland)

Volumn 85, Issue 4, 2013, Pages 223-227

  Lamm, W ^a   Drach Schauer, B ^a   Eder, S ^a   Drach, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bortezomib; Multiple myeloma; Side effects; Subcutaneous administration

Indexed keywords

ANTIEMETIC AGENT; BORTEZOMIB; DEXAMETHASONE; MELPHALAN; PREDNISONE; THALIDOMIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INJECTION SITE REACTION; LOCAL SKIN REACTION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; APHERESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; DRUG DOSE REDUCTION; GASTROINTESTINAL TOXICITY; LIGHT CHAIN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TUMOR ENGRAFTMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; PYRAZINES; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84888272756     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000355197     Document Type: Article

References (15)

1. Bird JM, Owen RG, D'Sa, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum: Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011; 154: 32-75.
2. Frelay J, Bray F, Sankila R, Parkin DM: EUCAN: Cancer Incidence, Mortality and Prevalence in the European Union 1998, version 5.0. IARC Cancer Base No 4. Lyon, IARC Press, 1999.
3. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1996; 16: 3832-3842.
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
5. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working Party: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
6. Engelhardt M, Kleber M, Udi J, Wasch R, Spencer A, Patriarca F, Knop S, Bruno B, Gramatzki M, Morabito F, Kropff M, Neri A, Sezer O, Hajek R, Bunjes D, Boccadoro M, Straka C, Cavo M, Polliack A, Einsele H, Palumbo A: Consensus statement from European experts on the diagnosis, management and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010; 51; 1424-1443.
7. Millenium Pharmaceuticals: Velcade (bortezomib) for Injection. Prescribing Information (rev 10). Cambridge, Millenium Pharmaceuticals, 2009.
8. Antoine JC, Camdessanche JP: Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007; 6: 75-86.
9. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harrouseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blade J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dosemodification guideline. Br J Haematol 2009; 144: 895-903.
10. Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, Harrouseau JL: Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008; 93: 1908-1911.
11. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harrousseau JL: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431-440.
12. Blade J, Samson D, Reese D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
13. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946-2955.
14. Einsele H, Liebisch P, Langer C, et al: Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previous-ly untreated multiple myeloma (German DSMM Xia trial) (abstract 131). Blood 2009; 114: 59.
15. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.